Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies

Transplant International

Volumn 27, Issue 8, 2014, Pages 775-783

  Croze, Laure Emmanuelle ^a   Tetaz, Rachel ^a   Roustit, Matthieu ^a,b   Malvezzi, Paolo ^a   Janbon, Bénédicte ^a   Jouve, Thomas ^a   Pinel, Nicole ^a   Masson, Dominique ^c   Quesada, Jean Louis ^a   Bayle, François ^a   Zaoui, Philippe ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b University Grenoble Alpes   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Antibody mediated rejection; donor specific HLA antibodies; kidney transplantation; mTOR inhibitors

Indexed keywords

ANTIBODY; AZATHIOPRINE; CREATININE; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; EVEROLIMUS; HLA ANTIBODY; HLA DQB1 ANTIGEN; INTERLEUKIN 2 RECEPTOR; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; CALCINEURIN INHIBITOR; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNIZATION; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; ANTAGONISTS AND INHIBITORS; DONOR; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; RISK;

ADULT; AGED; CALCINEURIN INHIBITORS; COHORT STUDIES; FEMALE; GRAFT REJECTION; HLA-DQ BETA-CHAINS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TISSUE DONORS; TOR SERINE-THREONINE KINASES;

EID: 84905015677     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12330     Document Type: Article

References (34)

1. Chapman JR,. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693.
2. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
3. Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K,. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22: 366.
4. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
5. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
6. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
7. Holdaas H, Rostaing L, Seron D, et al,. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011; 92: 410.
8. Colvin RB,. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
9. Crespo M, Pascual M, Tolkoff-Rubin N, et al,. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
10. Mauiyyedi S, Crespo M, Collins AB, et al,. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
11. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW,. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
12. Mao Q, Terasaki PI, Cai J, et al,. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
13. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
14. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
15. Terasaki PI, Ozawa M,. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
16. Mizutani K, Terasaki P, Rosen A, et al,. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
17. Lebranchu Y, Thierry A, Thervet E, et al,. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665.
18. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
19. Kamar N, Del Bello A, Congy-Jolivet N, et al,. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013; 27: 455.
20. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
21. Flechner SM,. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87 (8 Suppl): S1.
22. Buchler M, Caillard S, Barbier S, et al,. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
23. Hamdy AF, El-Agroudy AE, Bakr MA, et al,. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005; 5: 2531.
24. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
25. Stephany BR, Augustine JJ, Krishnamurthi V, et al,. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368.
26. Larson TS, Dean PG, Stegall MD, et al,. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
27. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
28. Guerra G, Srinivas TR, Meier-Kriesche HU,. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007; 20: 813.
29. Oberbauer R,. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus. Transplantation 2009; 87 (8 Suppl): S7.
30. Hamdy AF, Bakr MA, Ghoneim MA,. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008; 19: 1225.
31. Ozawa M, Rebellato LM, Terasaki PI, et al,. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: greenville experience. Clin Transpl. 2006; 20: 265.
32. Duquesnoy RJ, Awadalla Y, Lomago J, et al,. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transpl Immunol 2008; 18: 352.
33. Kobayashi T, Maruya E, Niwa M, et al,. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Hum Immunol 2011; 72: 11.
34. Kaczmarek I, Deutsch MA, Kauke T, et al,. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6: 229.